Approximately 15% of all breast tumors are triple-negative BCa (TNBC) [8], as they lack the expression of ER, PR, or HER2. Patients with triple-negative tumors are at higher risk of distant relapse [9] and have systemic chemotherapy as the only treatment option. This evidence concerns the gene ERBB2 and breast neoplasm.